Amgen's most recent trend suggests a bearish bias. One trading opportunity on Amgen is a Bear Call Spread using a strike $160.00 short call and a strike $170.00 long call offers a potential 27.23% return on risk over the next 31 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $160.00 by expiration. The full premium credit of $2.14 would be kept by the premium seller. The risk of $7.86 would be incurred if the stock rose above the $170.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Amgen is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Amgen is bearish.
The RSI indicator is at 34.71 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
4:01 pm Amgen to present Phase 3 Imlygic data at the 2015 International Congress of the Society for Melanoma Research
Mon, 16 Nov 2015 21:01:00 GMT
Amgen to Present IMLYGIC™ (Talimogene Laherparepvec) Data at the 2015 International Congress of the Society for Melanoma Research
Mon, 16 Nov 2015 21:00:00 GMT
PR Newswire – THOUSAND OAKS, Calif., Nov. 16, 2015 /PRNewswire/ — Amgen (AMGN) today announced that the Company will present eight IMLYGICTM (talimogene laherparepvec) abstracts, including data from the Phase 3 trial and new data from its Phase 1b combination trial with Merck's anti-PD-1 therapy, at the 12th International Congress of the Society for Melanoma Research (SMR), to be held on Nov. 18-21 in San Francisco. “The analyses from our Phase 3 monotherapy trial confirm the clinical significance of durable responses and the benefit IMLYGIC may bring to patients living with metastatic melanoma,” said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. The Phase 1b data on IMLYGIC in combination with an investigational use of Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with unresectable metastatic melanoma (NCT02263508) has been accepted as a late-breaking abstract.
Billionaire Dan Loeb Grows Bearish on the Market As Short Positions Outpace His Conviction Buys
Mon, 16 Nov 2015 17:36:26 GMT
Amgen’s Bone and Nephrology Drugs Register Solid Growth in 3Q15
Mon, 16 Nov 2015 17:04:43 GMT
Five Mind Blowing Charts: AAPL, NFLX, AMZN, FB, GILD
Mon, 16 Nov 2015 15:05:15 GMT
Related Posts
Also on Market Tamer…
Follow Us on Facebook